Cost-effectiveness of anti-EGFR antibodies as first-line treatment in RAS wild type (WT) metastatic colorectal cancer (mCRC) in Hong Kong

View Statistics Email Alert RSS Feed

Grant Data
Project Title
Cost-effectiveness of anti-EGFR antibodies as first-line treatment in RAS wild type (WT) metastatic colorectal cancer (mCRC) in Hong Kong
Principal Investigator
Dr Chiang, Chi Leung   (Principal Investigator (PI))
Co-Investigator(s)
Dr Choi Cheuk Wai   (Co-Investigator)
Dr Lam Ka On   (Co-Investigator)
Dr Lee Victor Ho Fun   (Co-Investigator)
Dr Wong Oi Ling   (Co-Investigator)
Duration
18
Start Date
2018-04-01
Completion Date
2020-08-11
Amount
99627
Conference Title
Cost-effectiveness of anti-EGFR antibodies as first-line treatment in RAS wild type (WT) metastatic colorectal cancer (mCRC) in Hong Kong
Keywords
anti-EGFR monoclonal, cost-effectiveness, first-line therapy, metastatic colorectal, RAS
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
15161781
Grant Type
Health and Medical Research Fund - Mini Grant
Funding Year
2017
Status
Completed
Objectives
To evaluate the cost effectiveness of anti-EGFR monoclonal antibodies (mAb) as first-line treatment in RAS wild type (WT) metastatic colorectal cancer patients (mCRC).